CD274 and neoplasm: Although immunohistochemistry (IHC) analysis of PD-L1 expression in tumor tissue has been approved as a companion test for each of the five therapeutic antibodies for PD-1/PD-L1 immune checkpoint blockade, heterogeneity of PD-L1 expression contributes to uncertainty in determining the PD-L1 status of patient tumors34–36.